SNRPB and CEP290, predicting the prognosis of diffuse large B cell lymphoma and associated with tumour immune microenvironment
Open Access
- 3 December 2024
- journal article
- research article
- Published by Taylor & Francis in Annals of Medicine
- Vol. 56 (1) , 2425065
Abstract
Diffuse large B-cell lymphoma (DLBCL), the most prevalent type of non-Hodgkin’s lymphoma, exhibits significant correlations with efferocytosis-related molecules (ERMs) concerning invasion, metastasis, and clinical outcomes. This study aims to establish an efferocytosis-related gene signature specifically linked to DLBCL. Key module genes linked to DLBCL were identified via weighted gene co-expression network analysis (WGCNA) in GSE32018. Univariate Cox analysis of GSE31312 revealed ERMs associated with DLBCL survival. Differential expression analysis identified differentially expressed genes (DEGs) between DLBCL subtypes and normal samples. Venn diagram analysis identified common DEGs and key module genes. A DLBCL gene signature was built by using univariate Cox and least absolute shrinkage and selection operator (LASSO) analysis. Gene functional enrichment, immune microenvironment, and immunotherapy analyses compared two risk subgroups. Prognostic gene expression was validated at the single-cell level. In the GSE32018 dataset, 1760 key module genes related to DLBCL were identified. Using GSE31312, 14 ERMs associated with DLBCL prognosis were determined.Then, an ERMs-related prognostic signature, including small nuclear ribonucleoprotein polypeptides B (SNRPB) and centrosomal protein 290 (CEP290), was established. Independent prognostic analysis showed that the RiskScore derived from this signature was a prognostic factor. Significant immune microenvironment differences were observed between two risk subgroups. Additionally, chemotherapeutic drug sensitivity results indicated the signature could predict therapeutic response. Eventually, expression of SNRPB and CEP290 was confirmed in B cells. The prognostic signature comprised of SNRPB and CEP290 based on ERMs-DEGs was established, providing a theoretical basis and reference value for DLBCL research.Keywords
Funding Information
- Sanming Project of Medicine in Shenzen Municipality (SZSM201911004)
- Shenzhen Science and Technology Innovation Commission (JCYJ20230807110659001)
This publication has 56 references indexed in Scilit:
- Long Noncoding RNAs as New Architects in Cancer Epigenetics, Prognostic Biomarkers, and Potential Therapeutic TargetsBioMed Research International, 2015
- limma powers differential expression analyses for RNA-sequencing and microarray studiesNucleic Acids Research, 2015
- Two Novel Mutations in the C-Terminal Region of Centrosomal Protein 290 (CEP290) Result in Classic Joubert SyndromeJournal of Child Neurology, 2014
- clusterProfiler: an R Package for Comparing Biological Themes Among Gene ClustersOMICS: A Journal of Integrative Biology, 2012
- Focus on Molecules: Centrosomal protein 290 (CEP290)Experimental Eye Research, 2011
- ConsensusClusterPlus: a class discovery tool with confidence assessments and item trackingBioinformatics, 2010
- The novel triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO) induces apoptosis of human diffuse large B-cell lymphoma cells through a peroxisome proliferator-activated receptor γ-independent pathwayExperimental Hematology, 2006
- Cytoscape: A Software Environment for Integrated Models of Biomolecular Interaction NetworksGenome Research, 2003
- Analysis of genes for human snRNP Sm-D1 protein and identification of the promoter sequence which shows segmental homology to the promoters of Sm-E and U1 snRNA genesGene, 1997
- CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clonesNature, 1992